{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(2)"],"submitter":["Planchard D"],"pubmed_abstract":["<h4>Background</h4>The first-line (1L) standard of care for B-Raf proto-oncogene (BRAF)<sup>V600E</sup>-mutant metastatic non-small cell lung cancer is BRAF inhibitor dabrafenib with MEK inhibitor trametinib (D + T). Combination therapy with encorafenib and binimetinib (E + B) has recently demonstrated clinical benefit in this setting in the single-arm, phase II PHAROS trial. We evaluated the relative efficacy and safety of E + B versus D + T in 1L using an unanchored matching-adjusted indirect comparison.<h4>Material and methods</h4>Individual patient data for E + B from PHAROS were matched on validated adjustment factors to aggregate data for D + T from Study BRF113928. The relative efficacy and safety of E + B versus D + T were assessed using weighted Cox proportional hazards models for"],"journal":["ESMO open"],"pagination":["106051"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12865620"],"repository":["biostudies-literature"],"pubmed_title":["Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF&lt;sup&gt;V600E&lt;/sup&gt;-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison."],"pmcid":["PMC12865620"],"pubmed_authors":["Le Reun C","Macabeo B","Grouin JM","Planchard D","Mazieres J","Boussahoua M","Luttenauer H"],"additional_accession":[]},"is_claimable":false,"name":"Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF&lt;sup&gt;V600E&lt;/sup&gt;-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.","description":"<h4>Background</h4>The first-line (1L) standard of care for B-Raf proto-oncogene (BRAF)<sup>V600E</sup>-mutant metastatic non-small cell lung cancer is BRAF inhibitor dabrafenib with MEK inhibitor trametinib (D + T). Combination therapy with encorafenib and binimetinib (E + B) has recently demonstrated clinical benefit in this setting in the single-arm, phase II PHAROS trial. We evaluated the relative efficacy and safety of E + B versus D + T in 1L using an unanchored matching-adjusted indirect comparison.<h4>Material and methods</h4>Individual patient data for E + B from PHAROS were matched on validated adjustment factors to aggregate data for D + T from Study BRF113928. The relative efficacy and safety of E + B versus D + T were assessed using weighted Cox proportional hazards models for","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T12:07:28.817Z","creation":"2026-07-04T03:12:38.608Z"},"accession":"S-EPMC12865620","cross_references":{"pubmed":["41604820"],"doi":["10.1016/j.esmoop.2025.106051"]}}